MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: chronic hepatitis B
MedXY News
EnglishTag

chronic hepatitis B

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Reevaluating EASL 2025 Criteria: Benefits of Nucleos(t)ide Analogues in Chronic Hepatitis B Beyond Current Recommendations
Gastroenterologycirrhosischronic hepatitis B

Reevaluating EASL 2025 Criteria: Benefits of Nucleos(t)ide Analogues in Chronic Hepatitis B Beyond Current Recommendations

By MedXY|Oct 20, 2026

This study demonstrates that nucleos(t)ide analogue therapy significantly reduces cirrhosis and hepatocellular carcinoma risk in specific HBeAg-positive chronic HBV infection phases beyond current EASL 2025 treatment indications.

Dynamic Immune Modulation by Pegylated Interferon-Alpha Post-NUC Withdrawal in Chronic Hepatitis B
Infectious Diseaseschronic hepatitis B
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Pegylated Interferon-Alpha

Dynamic Immune Modulation by Pegylated Interferon-Alpha Post-NUC Withdrawal in Chronic Hepatitis B

By MedXY|Oct 19, 2026

Pegylated interferon-alpha after nucleos(t)ide analog withdrawal induces coordinated expansion of regulatory B cells and contraction of HBV-specific T cells, impacting viral control and hepatic inflammation in HBeAg-negative chronic hepatit

Reevaluating Immune Tolerant Phase in Chronic Hepatitis B: High Transition Rates to Immune Active Disease and Clinical Implications from the RADICAL Consortium
Gastroenterologychronic hepatitis BFibrosis progression

Reevaluating Immune Tolerant Phase in Chronic Hepatitis B: High Transition Rates to Immune Active Disease and Clinical Implications from the RADICAL Consortium

By MedXY|Sep 23, 2026

The RADICAL consortium’s large-scale study reveals a high long-term transition rate from immune tolerant to immune active chronic hepatitis B, especially in patients with high-normal ALT, suggesting the need for closer monitoring and

AHB-137: First-in-Human Study Shows Promising Antiviral Activity and Safety in Chronic Hepatitis B Management
GastroenterologyAHB-137chronic hepatitis B

AHB-137: First-in-Human Study Shows Promising Antiviral Activity and Safety in Chronic Hepatitis B Management

By MedXY|Aug 16, 2026

AHB-137, an antisense oligonucleotide targeting HBV mRNA, demonstrated safety, favorable pharmacokinetics, and rapid HBsAg reduction in healthy volunteers and chronic hepatitis B patients, supporting further clinical development.

Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen
Gastroenterologychronic hepatitis BHBsAg seroclearance

Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen

By MedXY|Jul 14, 2026

This study evaluates the long-term incidence of liver cancer in chronic hepatitis B patients who clear hepatitis B surface antigen, finding significantly reduced cancer risk in younger patients without cirrhosis.

Functional Anti-preS1 Antibody Responses and Their Role in Viral Control in Chronic Hepatitis B
Clinical Updateschronic hepatitis BHBV therapy

Functional Anti-preS1 Antibody Responses and Their Role in Viral Control in Chronic Hepatitis B

By MedXY|Jun 28, 2026

This review synthesizes evidence on preS1 antigen and anti-preS1 IgG dynamics in chronic hepatitis B, highlighting their correlations with viral replication, liver inflammation, and functional cure, and elucidates the neutralising potential

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation
Gastroenterologychronic hepatitis Bcirrhosis

HBsAg Seroclearance Lowers Hepatocellular Carcinoma Risk Beyond Viral Suppression in Cirrhosis, but Does Not Reduce Hepatic Decompensation

By MedXY|Jun 10, 2026

In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint

Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection
GastroenterologyALG-000184Capsid Assembly Modulator

Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection

By MedXY|Feb 25, 2026

This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potenti

Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials
GastroenterologyAntisense oligonucleotidebepirovirsen

Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials

By MedXY|Jan 7, 2026

GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentiall

Elebsiran Combined with Pegylated Interferon Alfa for Chronic Hepatitis B: Advances from Phase 2 Clinical Trials
Clinical Updateschronic hepatitis BHBV therapy

Elebsiran Combined with Pegylated Interferon Alfa for Chronic Hepatitis B: Advances from Phase 2 Clinical Trials

By MedXY|Nov 13, 2025

Phase 2 studies demonstrate that elebsiran, a small interfering RNA, combined with PEG-IFNα, enhances sustained HBsAg loss rates in chronic HBV infection, offering a promising approach toward functional cure.

Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial
Clinical Updatesantiviral therapybepirovirsen

Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial

By MedXY|Sep 20, 2025

The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanc

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models